ArticleACS medicinal chemistry letters2025
A Miniaturized Chemical High Throughput Experimentation Plate to Enable Late-Stage Oxidation Screening and Scale-up.
Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemical methods for Late-Stage Oxidation (LSO) of advanced and complex molecules remain a highly relevant topic, with new and improved methods being reported annually. Despite the growing number of methodologies, the scope and limitations of these methods in bioactive molecules is largely unknown. We have designed a High-Throughput Experimentation (HTE) plate based on validated LSO methods, capable of screening compounds using only a few milligrams, to enhance our Late-Stage Functionalization (LSF) platform. Various projects at AbbVie have benefited from this plate, generating essential data for programs and creating new analogs for comprehensive Structure-Activity Relationship (SAR) analysis. We demonstrated the transformative capabilities of this approach by screening nine well-known drugs and analyzed the oxidized derivatives. This report highlights how this overlooked transformation can be an effective synthetic tool for medicinal chemistry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.